Document is current

Article History

Received: 10 May 2018

Accepted: 18 October 2018

First Online: 27 November 2018

Ethics approval and consent to participate

: This study was approved by the ethics committee of Sagamihara National Hospital and that of St. Marianna University School of Medicine. All of the blood samples were obtained with written informed consent.

: Not applicable.

: AH has received research funding from Chugai Pharmaceutical Co., Ltd. TM was a member of the Department of Lifetime Clinical Immunology (LCI) at Tokyo Medical and Dental University (TMDU). TMDU received unrestricted research grants for the Department of LCI from AbbVie GK, Ayumi Pharmaceutical Corporation, Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Towa Pharmaceutical Co., Ltd., and UCB Japan Co. Ltd., with which TMDU paid the salary of TM. ST was supported by research grants from nine pharmaceutical companies: Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and Teijin Pharma Limited. ST received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Pfizer Japan, Inc. The other authors have no financial or commercial conflicts of interest to declare.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.